期刊文献+

PET/CT在放射性粒子组织间种植治疗恶性实体肿瘤 被引量:8

PET/CT guided radioactive seed implantation in treating solid tumor
暂未订购
导出
摘要 放射性粒子组织间种植治疗优点是治疗区定位精确,靶区剂量高,正常组织的损伤小;与手术、化疗配合有互补作用可以保护机体功能及形态的效应。PET/CT同机完成了功能图象和解剖图像的融合。功能图象在肿瘤的诊断和治疗疗效评估以及预后的判断中突破了WHO传统的实体肿瘤影像学评价标准。其次,解剖图像和融合图像可以指导肿瘤活检、外科手术、放疗靶区确定等。PET/CT对肿瘤特异的分子靶点成像,定义肿瘤细胞的这一分子标记并给出治疗方案;治疗效果在功能和解剖图像上被发现、标记、评估。PET/CT引导下放射性粒子组织间种植治疗晚期恶性实体肿瘤的应用将克服常规粒子植入肿瘤治疗模式中存在的或多或少的经验主义,为实现肿瘤放射治疗的客观性和个体化提供可能,实现真正的生物适形放疗。 The advantages of radioisotopes seed implantation including: precise therapy area localization; high dose of target region; less impairment of normal tissue. Complied with surgeon and chemotherapy, radioisotopes seed implantation could protect function and morphological of patient body effectively. The functional imagines have advanced merits in tumor diagnosis, treating, therapy effects evaluation and prognostic judgements. The anatomy imaging could guide biopsy, surgeon and radiotherapy. PET/CT could process specify molecule target image on tumor, which might offer importance on formations for treatment plan and treatment effects. The disadvantages of traditional radioactive seed implantation are less objectivity and poor individualization, which could be overcome by PET/CT guided radioactive seed implantation. Biological conformal radiotherapy therapy can be implemented in the future by this way.
出处 《中国介入影像与治疗学》 CSCD 2006年第3期231-234,共4页 Chinese Journal of Interventional Imaging and Therapy
关键词 正电子发射体层摄影/计算机断层摄影术 X线 放射性同位素粒子 近距离放射疗法 实体肿瘤 Positron-emission tomography/Computerized tomography, X-ray Radioisotopes seed Brachytherapy Solid neoplasms
  • 相关文献

参考文献19

  • 1[1]Hu J,Galeone C,Lui R,et al.Smoking and lung cancer in Harbin,northeast China.Ann Oncol,2005,16(10):1605-1608.
  • 2[2]Guo X,Cui Z.Current diagnosis and treatment of pancreatic cancer in China.Pancreas,2005,31(1):13-22.
  • 3[3]He XW,Wu H.The progress of cancer targeted radioiodine therapy.Radiol Practice (Chinese),2005,20(1):87-90.
  • 4[4]Merrick GS,Butler WM,Galbreath RW,et al.Five year biochemical outcome following permanent interstitial brachytherapy for clini2 cal T1~T3 prostate cancer.Int J Radiat Oncol Biol Phys,2001,51(1):41-48.
  • 5[5]Williamson JF,Coursey BM,DeWerd LA,et al.Recommendations of the American Association of Physicists in Medicine on 103Pd interstitial source calibration and dosimetry:implications for specification and prescription.Med Phys,2000,27(4):634-642.
  • 6[6]Nag S,Ciezki JP,Cormack R,et al.Intraoperative planning and evaluation of permanent prostate brachytherapy:report of the American Brachytherapy Society.Int J Radiat Oncol Biol Phys,2001,51(5):1422-1430.
  • 7[7]Chen A,Galloway M,Landreneau R,et al.Intraoperative 125I brachytherapy for high risk stage I non-small cell lung carcinoma.Int J Radiat Oncol Biol Phys,1999,44(5):1057-1063.
  • 8[8]Merrick GS,Butler WM,Galbreath RW,et al.Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ confirmed carcinoma of the prostate gland.Int J Radiat Oncol Biol Phys,2002,52(3):664-673.
  • 9[9]Yue L.Implantation with 125 I seeds for the treatment of tumor.Foreign Medical Sciences,Section of Radiation Medicine and Nuclear Medicine,2001,25(1):23-26
  • 10[10]Galalae RM,Kovacs G,Schultze J,et al.Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer.Int J Radiat Oncol Biol Phys,2002,52(1):81-90.

同被引文献67

引证文献8

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部